Midjourney, widely known for its AI-driven text-to-image innovations, is branching into the medical field with a groundbreaking technology release. On June 17, the company announced its first hardware product, the Midjourney Scanner. This full-body ultrasound device aims to revolutionize conventional scanning methods by providing rapid imaging without the use of radiation or magnetic fields. As part of this expansion, a new division, Midjourney Medical, will oversee production, emphasizing a potentially more cost-effective alternative to traditional MRI processes. The strategy reflects a broader industry trend toward health tech advancements that aim to simplify procedures and reduce costs.
The introduction of Midjourney’s scanner adds a fresh dimension to a market historically led by companies like Siemens Healthineers, GE Healthcare, and Philips. Traditional MRI scans typically involve significant expenses and time commitments, requiring scheduled appointments and specialized equipment. Midjourney’s approach, by contrast, seeks to circumvent these complexities by offering a quicker, potentially more affordable solution, aiming to democratize access to full-body scans in non-clinical environments. In previous developments, broader access to diagnostic imaging suffered from requiring significant infrastructure, a hurdle that firms like Midjourney seek to lower.
What Powers the New Scanner?
Underpinning the Midjourney Scanner is technology licensed from Butterfly Network, a company recognized for its semiconductor ultrasound innovations. A significant financial agreement between Midjourney and Butterfly backs this collaboration, with a five-year plan potentially amounting to $74 million. Joseph DeVivo, CEO of Butterfly Network, acknowledged the partnership as a significant commercial opportunity for his firm. According to Midjourney, the scanner’s prototype features 40 Butterfly Ultrasound-on-Chip modules. Future iterations are likely to integrate even more advanced components.
“We’re not even using any AI in this yet,” stated Midjourney CEO David Holz.
The first execution plan for this scanner is not solely in medical facilities but at a wellness center dubbed the “Midjourney Spa”. This unconventional rollout covers a 25,000-square-foot area in San Francisco, complete with amenities like saunas and hot tubs. Visitors can undergo scans as an ancillary service, suggesting an alternative path for introducing new medical devices to the public without clinical settings.
Is Regulatory Approval on the Horizon?
Currently, the Midjourney Scanner does not possess FDA clearance for diagnostic applications. Its initial offering will focus on body composition mapping, which is not subject to strict regulatory requirements. Midjourney will phase in FDA approvals for diagnostic functions over time. The device has already been used for trial scans on a small group, with a broader clinical trial and development pipeline in progress, indicating a strategic path to eventual regulatory approval.
“No such device has ever been built until now,” expressed David Holz during a launch event.
Besides this project, Midjourney has diversified its portfolio into eight ventures, balancing between hardware and software advancements. Ambitiously, the company targets global deployment with an eventual 50,000 units and facilitating up to one billion scans monthly by 2031. This underscores a substantial commitment to ongoing innovation and scaling within its new market segment.
While Midjourney’s technological leap represents a significant shift for the company, it is set against a backdrop of rigorous regulatory landscapes and longstanding incumbents in the field. The potential success of this diagnostic tool hinges on its ability to navigate these challenges and fulfill its promises of efficiency and cost reduction. For readers interested in emerging healthcare technology trends, the expansion of AI companies into medical hardware may provide new avenues for business and policy engagement.
